Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells
Phase 2Recruiting 2 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Cord Injury
Conditions
Spinal Cord Injury, Safety, Efficacy, Clinical Trial, Induced Pluripotent Stem Cells, Human Motor Neuron Progenitor, Transplantation, RCT
Trial Timeline
May 25, 2028 → May 26, 2031
NCT ID
NCT06974968About Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells is a phase 2 stage product being developed by Sun Pharmaceutical for Spinal Cord Injury. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06974968. Target conditions include Spinal Cord Injury, Safety, Efficacy.
What happened to similar drugs?
7 of 20 similar drugs in Spinal Cord Injury were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06974968 | Phase 2 | Recruiting |
| NCT06976229 | Phase 1 | Recruiting |
Competing Products
20 competing products in Spinal Cord Injury
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUN13837 injection + Placebo | Daiichi Sankyo | Phase 2 | 35 |
| Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg | Astellas Pharma | Phase 2 | 35 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 1 | 36 |
| Elezanumab | AbbVie | Pre-clinical | 30 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 35 |
| Ropivacaine + Bupivacaine | AstraZeneca | Phase 3 | 40 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 1 | 21 |
| Zolgensma | Novartis | Pre-clinical | 33 |
| BVS857 + Placebo | Novartis | Phase 2 | 35 |
| AVXS-101 | Novartis | Phase 1 | 29 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 44 |
| Onasemnogene Abeparvovec-brve | Novartis | Approved | 50 |
| Onasemnogene Abeparvovec-xioi | Novartis | Pre-clinical | 30 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 40 |
| branaplam | Novartis | Phase 1/2 | 32 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 40 |
| onasemnogene abeparvovec | Novartis | Phase 3 | 47 |
| onasemnogene abeparvovec-xioi | Novartis | Phase 3 | 40 |
| Risdiplam | Roche | Phase 1 | 29 |
| ATI355 | Novartis | Phase 1 | 29 |